DRG Market Assessment reports

The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

The market for multiple sclerosis (MS) disease-modifying therapies (DMTs) is crowded and competitive, as TG Therapeutics / Neuraxpharm’s Briumvi (ublituximab), Novartis’s Kesimpta (ofatumumab…

The treatment landscape for multiple sclerosis (MS) in the U.S. is rapidly evolving, with over 20 immunomodulatory disease-modifying therapies (DMTs) available and more in development. The market…

No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of MS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of MS for each country, as well…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple sclerosis patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…